EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013 and 2023

Dimitrios Karponis iD, Vasiliki Nikolaou, Alexander J Stratigos iD, Khaylen Mistry iD, Nick J Levell iD, Zoe C Venables iD

British Journal of Dermatology · 17.07.2026 · 195 (2) · 252-260

DOI: 10.1093/bjd/ljag177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 08.05.2026. Verfasst von Dimitrios Karponis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Norwich Medical School, University of East Anglia, Norwich, UK. Hauptthemen laut MEDLINE: Hutchinson's Melanotic Freckle, Skin Neoplasms, Melanoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Dermatology, Norfolk and Norwich University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lentigo maligna (LM) is a melanoma in situ usually found on the sun-exposed skin of older adults. Data on the risk of progression to lentigo maligna melanoma (LMM) are limited. Outcomes without surgical treatment are unknown.

Objectives

To describe the characteristics of patients with LM and LMM; to identify the incidence of LM and LMM in England from 2013 to 2023; and to calculate the survival of this cohort and estimate the risk of progression of LM to LMM, as well as its modifying factors.

Methods

Pseudonymized data for LM and LMM in England between 2013 and 2023 were provided by the National Disease Registration Service. Joinpoint regression was used to calculate incidence rates for LM and LMM. Kaplan–Meier curves were used for melanoma-specific and all-cause survival. The cumulative incidence of LMM after LM was calculated using a latency period of 6 months or 1 year, for identical or plausibly matching sites. Cox regression was used to explore the influence of covariates on survival and progression.

Results

Age-standardized incidence rates of LM [4.91–5.03 per 100 000 person-years (PY), annual percentage change (APC) 0.25, 95% confidence interval (CI) –2.68 to 3.35] and LMM (1.84–1.97 per 100 000 PY, APC 0.59, 95% CI –2.31 to 3.76) remained stable from 2013 to 2019, decreased in 2020 and increased in 2023 to higher than prepandemic levels. Patients with LM and LMM were more likely to die from other cancers or cardiovascular disease than from melanoma. Female sex (hazard ratio 0.56, 95% CI 0.49–0.66; P < 0.001) was protective, while increasing age conferred a higher risk of dying from melanoma. The risk of progression of LM to LMM was 1.0% (95% CI 0.8–1.1) at 10 years and increased with age and for tumours located on the head and neck.

Conclusions

The incidence rates of LM and LMM in the future will clarify if the post-COVID-19 pandemic increases are due to delayed presentations or a true rise in cases. The excellent net and overall survival of patients with LM, together with the low risk of progression to LMM, favour patient-centred discussions in the management of LM in older, frailer adults. The risk of progression without treatment requires further evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hutchinson's Melanotic FreckleSkin NeoplasmsMelanomaHumansFemaleEnglandAgedMaleIncidenceAged, 80 and overDisease ProgressionMiddle AgedKaplan-Meier Estimate

Autor:innen und Institutionen

  • Norwich Medical School, University of East Anglia, Norwich, UK.
  • Department of Dermatology, Norfolk and Norwich University Hospitals, Norwich, UK.
  • 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
  • National Disease Registration Service, Data and Analytics, NHS England, Leeds, UK.

ORCID-Profile: Dimitrios Karponis, Alexander J Stratigos, Khaylen Mistry, Nick J Levell, Zoe C Venables

Förderung

  • Department of Dermatology, Norfolk and Norwich University Hospital

Zitieren

APA

Karponis, D., Nikolaou, V., Stratigos, A. J., Mistry, K., Levell, N. J., & Venables, Z. C. (2026). Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013 and 2023. British Journal of Dermatology, 195(2), 252-260. https://doi.org/10.1093/bjd/ljag177

Vancouver

Karponis D, Nikolaou V, Stratigos AJ, Mistry K, Levell NJ, Venables ZC. Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013 and 2023. British Journal of Dermatology. 2026;195(2):252-260. doi:10.1093/bjd/ljag177

BibTeX
@article{Karponis2026,
  author = {Karponis, Dimitrios and Nikolaou, Vasiliki and Stratigos, Alexander J and Mistry, Khaylen and Levell, Nick J and Venables, Zoe C},
  title = {Epidemiology of lentigo maligna and lentigo maligna melanoma in England between 2013 and 2023},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {2},
  pages = {252--260},
  doi = {10.1093/bjd/ljag177}
}
Kostenlos starten →